Back
Speaker illustration

Doctor Yiyuan Huang

The Second Xiangya Hospital of Central South University, Changsha (China)

Member of:

European Society of Cardiology

Dr. Huang focused on studying the mechanism and treatment of HCM and Valvular Heart Disease since 2016. He and coleagues found a Novel drug targeting cardiomyocytes which directly inhibit myofilament contraction might prevent HCM disease phenotypic expression and progression, and developed a novel device to relieve the left ventricular outflow tract (LVOT) obstruction in patients with HCM.

Presentations

Trans-femoral transcatheter intramyocardial septal radiofrequency ablation: a novel therapeutic approach for obstructive hypertrophic cardiomyopathy

Event: ESC Congress 2024

Topic: Hypertrophic Cardiomyopathy

Session: Hypertrophic obstructive cardiomyopathy (HOCM): clearing the roadblock

Access
Like
Thumbnail

Association between silent cerebral embolism and cognitive alterations following transcatheter aortic valve replacement in bicuspid versus tricuspid aortic valve patients

Event: ESC Congress 2024

Topic: Intervention

Session: Prosthetic heart valves: preventing thrombosis and stroke

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources